{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:31:41Z","timestamp":1793255501130,"version":"4.5.0"},"reference-count":135,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The use of stimulant medications has expanded substantially beyond the traditional treatment of attention-deficit\/hyperactivity disorder (ADHD) to encompass a variety of other clinical conditions. Understanding the safety of these medications is important as their use increases across diverse patient populations.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the safety of stimulant medications as reported in randomized clinical trials (RCTs) investigating methylphenidate, lisdexamfetamine, and other amphetamines.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>A comprehensive literature search was conducted from July 1, 2024, through February 28, 2025, using CINAHL, Embase, PubMed or MEDLINE, ScienceDirect, and Web of Science for studies published since 2000. Keywords included safety, adverse event, side effect, amphetamine, dextroamphetamine, stimulant, lisdexamfetamine,<\/jats:italic> and methylphenidate<\/jats:italic>.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>RCTs published between January 1, 2000, and December 13, 2024, were included. These trials investigated the safety of stimulants in various clinical conditions, including ADHD, depression, binge eating disorder, schizophrenia, Alzheimer disease, and stimulant use disorders as well as in healthy individuals. Trials not focused on safety or adverse events (AEs) of stimulants, nonoriginal research, nonhuman research, trials with concomitant prescriptions other than stimulants, and trials without a placebo group were excluded.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>Data extraction followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline. Independent reviewers extracted study data, and a random-effects model was used to pool results. Heterogeneity was assessed using the I<\/jats:italic>2<\/jats:sup> statistic.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the risk ratio (RR) of developing any AE in participants taking stimulants vs placebo.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 93 RCTs were included after exclusions. The methodological quality assessment of the included trials showed overall low or unclear risk of bias. Trials with a duration of up to 52 weeks showed that stimulant medications were associated with an increased risk of overall AEs compared with placebo (RR, 1.34; 90% CI, 1.27-1.41), with high heterogeneity (I<\/jats:italic>2<\/jats:sup>\u2009=\u200967%). Statistical significance of this finding was maintained when subgroups (ie, methylphenidate, lisdexamfetamine, and other amphetamines) were separately analyzed.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This meta-analysis found an increased risk of overall AEs associated with stimulants compared with placebo. Future research could provide more standardized and consistent assessments of this outcome and may improve understanding about misuse risk.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.9492","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T15:30:40Z","timestamp":1746804640000},"page":"e259492","source":"Crossref","is-referenced-by-count":17,"title":["Safety of Stimulants Across Patient Populations"],"prefix":"10.1001","volume":"8","author":[{"given":"Henrique Nunes Pereira","family":"Oliva","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven"},{"name":"Connecticut Mental Health Center, New Haven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Paiva","family":"Prudente","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidade Federal de Goi\u00e1s, Goi\u00e2nia, Goi\u00e1s, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia F.","family":"Mayerson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven"},{"name":"Connecticut Mental Health Center, New Haven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella M.","family":"Mignosa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven"},{"name":"Connecticut Mental Health Center, New Haven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Oliveira","family":"Oliva","sequence":"additional","affiliation":[{"name":"School of Medicine, Centro Universitario FIPMoc, Montes Claros, Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc N.","family":"Potenza","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Connecticut Mental Health Center, New Haven"},{"name":"Child Study Center, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Department of Neuroscience, Yale University, New Haven, Connecticut"},{"name":"Connecticut Council on Problem Gambling, Wethersfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwole O.","family":"Jegede","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Connecticut Mental Health Center, New Haven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo A.","family":"Angarita","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven"},{"name":"Connecticut Mental Health Center, New Haven"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"zoi250343r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101524","article-title":"Trends in characteristics of the recipients of new prescription stimulants between years 2010 and 2020 in the United States: an observational cohort study.","volume":"50","author":"Brumbaugh","year":"2022","journal-title":"eClinicalMedicine"},{"issue":"13","key":"zoi250343r2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.15585\/mmwr.mm7213a1","article-title":"Trends in stimulant prescription fills among commercially insured children and adults\u2014United States, 2016-2021.","volume":"72","author":"Danielson","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi250343r3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/eat.23650","article-title":"The potential role of stimulants in treating eating disorders.","volume":"55","author":"Keshen","year":"2022","journal-title":"Int J Eat Disord"},{"key":"zoi250343r4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jad.2021.05.119","article-title":"Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis.","volume":"292","author":"Bahji","year":"2021","journal-title":"J Affect Disord"},{"issue":"1","key":"zoi250343r5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","article-title":"Recently approved and upcoming treatments for narcolepsy.","volume":"34","author":"Thorpy","year":"2020","journal-title":"CNS Drugs"},{"issue":"8","key":"zoi250343r6","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s00213-020-05563-3","article-title":"Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.","volume":"237","author":"Tardelli","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"zoi250343r7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/17512433.2022.2112950","article-title":"What is the potential for abuse of lisdexamfetamine in adults? a preclinical and clinical literature review and expert opinion.","volume":"15","author":"Carton","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"zoi250343r8","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jadohealth.2020.12.006","article-title":"Use of stimulant diversion prevention strategies in pediatric primary care and associations with provider characteristics.","volume":"68","author":"McGuier","year":"2021","journal-title":"J Adolesc Health"},{"issue":"2","key":"zoi250343r9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1001\/jamapsychiatry.2023.4294","article-title":"Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases.","volume":"81","author":"Zhang","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"zoi250343r10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/jamapediatrics.2019.0905","article-title":"Evaluation of methylphenidate safety and maximum-dose titration rationale in attention-deficit\/hyperactivity disorder: a meta-analysis.","volume":"173","author":"Ching","year":"2019","journal-title":"JAMA Pediatr"},{"issue":"3","key":"zoi250343r11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/jpc.16380","article-title":"Safety of stimulant medications for attention deficit hyperactivity disorder in paediatric congenital heart disease.","volume":"59","author":"Chung","year":"2023","journal-title":"J Paediatr Child Health"},{"issue":"1","key":"zoi250343r12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.psc.2018.10.011","article-title":"Binge-eating disorder.","volume":"42","author":"Hilbert","year":"2019","journal-title":"Psychiatr Clin North Am"},{"key":"zoi250343r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107627","article-title":"Methylphenidate for attention problems in epilepsy patients: safety and efficacy.","volume":"115","author":"Leeman-Markowski","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"5","key":"zoi250343r14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1469-7610.1996.tb01445.x","article-title":"Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder: clinical efficacy and side-effects.","volume":"37","author":"Buitelaar","year":"1996","journal-title":"J Child Psychol Psychiatry"},{"issue":"9","key":"zoi250343r15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0003-9993(98)90169-1","article-title":"Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study.","volume":"79","author":"Grade","year":"1998","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"zoi250343r16","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/s41380-021-01391-9","article-title":"The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit\/hyperactivity disorder in children and adolescents: a meta-analysis.","volume":"27","author":"Farhat","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"1","key":"zoi250343r17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41380-021-01134-w","article-title":"Placebo and nocebo responses in randomised, controlled trials of medications for ADHD: a systematic review and meta-analysis.","volume":"27","author":"Faraone","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"8","key":"zoi250343r18","first-page":"39","article-title":"Lisdexamfetamine dimesylate: the first prodrug stimulant.","volume":"4","author":"Goodman","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"1","key":"zoi250343r19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews.","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"zoi250343r20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"zoi250343r21","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias.","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"3","key":"zoi250343r22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1037\/0033-2909.86.3.638","article-title":"The file drawer problem and tolerance for null results.","volume":"86","author":"Rosenthal","year":"1979","journal-title":"Psychol Bull"},{"issue":"7109","key":"zoi250343r23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"3","key":"zoi250343r27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/EDE.0000000000001177","article-title":"Toward causally interpretable meta-analysis: transporting inferences from multiple randomized trials to a new target population.","volume":"31","author":"Dahabreh","year":"2020","journal-title":"Epidemiology"},{"issue":"7","key":"zoi250343r28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/03007995.2022.2076474","article-title":"Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate.","volume":"38","author":"Shram","year":"2022","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"zoi250343r29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/a-1207-9851","article-title":"Safety profile of methylphenidate under long-term treatment in adult ADHD patients: results of the COMPAS Study.","volume":"53","author":"Kis","year":"2020","journal-title":"Pharmacopsychiatry"},{"issue":"9","key":"zoi250343r30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.4088\/JCP.v69n0911","article-title":"Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study.","volume":"69","author":"Spencer","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"zoi250343r31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/01.CHI.0000046863.56865.FE","article-title":"Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.","volume":"42","author":"McCracken","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"zoi250343r32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/cap.2017.0095","article-title":"Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit\/hyperactivity disorder.","volume":"28","author":"Childress","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"zoi250343r33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1089\/cap.2020.0005","article-title":"A phase 3, randomized double-blind study of the efficacy and safety of low-dose SHP465 mixed amphetamine salts extended-release in children with attention-deficit\/hyperactivity disorder.","volume":"30","author":"Mattingly","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"zoi250343r34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.clinthera.2006.02.011","article-title":"Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit\/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.","volume":"28","author":"Spencer","year":"2006","journal-title":"Clin Ther"},{"issue":"9","key":"zoi250343r35","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.biopsych.2007.04.015","article-title":"Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.","volume":"62","author":"Biederman","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"1","key":"zoi250343r36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/cap.2017.0053","article-title":"SHP465 mixed amphetamine salts in the treatment of attention-deficit\/hyperactivity disorder in children and adolescents: results of a randomized, double-blind placebo-controlled study.","volume":"28","author":"Brams","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"zoi250343r37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1089\/cap.2014.0176","article-title":"The efficacy and safety of Evekeo, Racemic amphetamine sulfate, for treatment of attention-deficit\/hyperactivity disorder symptoms: a multicenter, dose-optimized, double-blind, randomized, placebo-controlled crossover laboratory classroom study.","volume":"25","author":"Childress","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"zoi250343r38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/cap.2021.0107","article-title":"Efficacy and safety of dextroamphetamine transdermal system for the treatment of attention-deficit\/hyperactivity disorder in children and adolescents: results from a pivotal phase 2 study.","volume":"32","author":"Cutler","year":"2022","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"zoi250343r39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaac.2011.01.007","article-title":"Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder.","volume":"50","author":"Findling","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"zoi250343r40","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14438","article-title":"Randomized, double-blind, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of amphetamine extended-release tablets in adults with attention-deficit\/hyperactivity disorder.","volume":"83","author":"Cutler","year":"2022","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"zoi250343r41","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m13927","article-title":"A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AR19, a manipulation-resistant formulation of amphetamine sulfate, in adults with attention-deficit\/hyperactivity disorder.","volume":"82","author":"Faraone","year":"2021","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"zoi250343r42","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40263-017-0455-7","article-title":"Efficacy and safety of SHP465 mixed amphetamine salts in the treatment of attention-deficit\/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled, forced-dose clinical study.","volume":"31","author":"Weisler","year":"2017","journal-title":"CNS Drugs"},{"key":"zoi250343r43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1744-9081-6-34","article-title":"Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder: novel findings using a simulated adult workplace environment design.","volume":"6","author":"Wigal","year":"2010","journal-title":"Behav Brain Funct"},{"issue":"3","key":"zoi250343r44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/1087054711427299","article-title":"Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD.","volume":"16","author":"Dupaul","year":"2012","journal-title":"J Atten Disord"},{"issue":"1","key":"zoi250343r45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1461145711001131","article-title":"Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD.","volume":"15","author":"Buitelaar","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"issue":"8","key":"zoi250343r46","doi-asserted-by":"publisher","first-page":"810","DOI":"10.4088\/JCP.12m08099","article-title":"Safety and efficacy of methylphenidate for apathy in Alzheimer\u2019s disease: a randomized, placebo-controlled trial.","volume":"74","author":"Rosenberg","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"zoi250343r47","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3109\/15622975.2013.868925","article-title":"A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit\/hyperactivity disorder in Japan.","volume":"15","author":"Takahashi","year":"2014","journal-title":"World J Biol Psychiatry"},{"issue":"6","key":"zoi250343r48","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/01.jcp.0000246212.03530.fd","article-title":"A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.","volume":"26","author":"Patkar","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"zoi250343r49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","article-title":"Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.","volume":"72","author":"McElroy","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"zoi250343r50","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/10870547211025610","article-title":"Randomized, double-blind, placebo-controlled, parallel-group, adult laboratory classroom study of the efficacy and safety of PRC-063 (extended-release methylphenidate) for the treatment of ADHD.","volume":"26","author":"Childress","year":"2022","journal-title":"J Atten Disord"},{"issue":"12","key":"zoi250343r51","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2352-4642(22)00279-6","article-title":"Efficacy and safety of methylphenidate and behavioural parent training for children aged 3-5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial.","volume":"6","author":"Sugaya","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"zoi250343r52","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1542\/peds.108.4.883","article-title":"Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit\/hyperactivity disorder.","volume":"108","author":"Wolraich","year":"2001","journal-title":"Pediatrics"},{"issue":"12","key":"zoi250343r53","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2165\/00148581-200305120-00006","article-title":"Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.","volume":"5","author":"Biederman","year":"2003","journal-title":"Paediatr Drugs"},{"issue":"1","key":"zoi250343r54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/cap.2019.0070","article-title":"A randomized, double-blind, placebo-controlled study of HLD200, a delayed-release and extended-release methylphenidate, in children with attention-deficit\/hyperactivity disorder: an evaluation of safety and efficacy throughout the day and across settings.","volume":"30","author":"Childress","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"zoi250343r55","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1089\/cap.2017.0084","article-title":"Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit\/hyperactivity disorder.","volume":"27","author":"Pliszka","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"zoi250343r56","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1089\/cap.2020.0109","article-title":"Efficacy and safety of multilayer, extended-release methylphenidate (PRC-063) in children 6-12 years of age with attention-deficit\/hyperactivity disorder: a laboratory classroom study.","volume":"30","author":"Childress","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"zoi250343r57","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1089\/cap.2007.0015","article-title":"Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit\/hyperactivity disorder: a 12-hour laboratory classroom study.","volume":"18","author":"Muniz","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"zoi250343r58","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.4088\/JCP.v69n1213","article-title":"Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit\/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.","volume":"69","author":"Chronis-Tuscano","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"zoi250343r59","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1089\/cap.2011.0014","article-title":"Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit\/hyperactivity disorder.","volume":"21","author":"Winhusen","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"zoi250343r60","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1089\/cap.2021.0034","article-title":"Efficacy and safety of a long-acting multilayer-release methylphenidate formulation (PRC-063) in the treatment of adolescent attention-deficit\/hyperactivity disorder: a randomized, double-blind clinical trial with a 6-month open-label extension.","volume":"31","author":"Weiss","year":"2021","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"zoi250343r61","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archpedi.160.1.82","article-title":"Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit\/hyperactivity disorder.","volume":"160","author":"Wilens","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"zoi250343r62","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3109\/15622975.2011.600333","article-title":"Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit\/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.","volume":"14","author":"Casas","year":"2013","journal-title":"World J Biol Psychiatry"},{"issue":"6","key":"zoi250343r63","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/JCP.0000000000000205","article-title":"Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.","volume":"34","author":"Martin","year":"2014","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"zoi250343r64","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.euroneuro.2017.11.003","article-title":"A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study).","volume":"28","author":"Hegerl","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10034","key":"zoi250343r65","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/S0140-6736(16)00205-1","article-title":"Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial.","volume":"387","author":"Nuijten","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"zoi250343r66","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0269881109103113","article-title":"Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.","volume":"23","author":"Jasinski","year":"2009","journal-title":"J Psychopharmacol"},{"issue":"2","key":"zoi250343r67","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/clpt.2010.307","article-title":"A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction.","volume":"89","author":"Galloway","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"zoi250343r68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/npr2.12082","article-title":"A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects.","volume":"40","author":"Ermer","year":"2020","journal-title":"Neuropsychopharmacol Rep"},{"issue":"9","key":"zoi250343r69","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4088\/JCP.v69n0903","article-title":"Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder.","volume":"69","author":"Adler","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"zoi250343r70","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/JCP.0b013e3181a390ce","article-title":"Efficacy and safety of OROS methylphenidate in adults with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.","volume":"29","author":"Adler","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"zoi250343r71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.neubiorev.2020.09.031","article-title":"Long term methylphenidate exposure and growth in children and adolescents with ADHD: a systematic review and meta-analysis.","volume":"120","author":"Carucci","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"zoi250343r72","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1471-244X-13-253","article-title":"Self-reported quality of life in adults with attention-deficit\/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.","volume":"13","author":"Adler","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"1","key":"zoi250343r73","doi-asserted-by":"publisher","DOI":"10.1542\/peds.107.1.e10","article-title":"Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects.","volume":"107","author":"Ahmann","year":"2001","journal-title":"Pediatrics"},{"issue":"8","key":"zoi250343r74","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/1087054711425772","article-title":"Time course of treatment effect of OROS\u00ae methylphenidate in children with ADHD.","volume":"16","author":"Armstrong","year":"2012","journal-title":"J Atten Disord"},{"issue":"9","key":"zoi250343r75","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.biopsych.2005.09.011","article-title":"A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit\/hyperactivity disorder.","volume":"59","author":"Biederman","year":"2006","journal-title":"Biol Psychiatry"},{"issue":"3","key":"zoi250343r76","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0149-2918(07)80083-X","article-title":"Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit\/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.","volume":"29","author":"Biederman","year":"2007","journal-title":"Clin Ther"},{"issue":"8","key":"zoi250343r77","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/070674370304800806","article-title":"The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder.","volume":"48","author":"Bouffard","year":"2003","journal-title":"Can J Psychiatry"},{"issue":"8","key":"zoi250343r78","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2165\/00023210-200822080-00006","article-title":"A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.","volume":"22","author":"Brams","year":"2008","journal-title":"CNS Drugs"},{"issue":"3","key":"zoi250343r79","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3810\/pgm.2011.05.2288","article-title":"Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.","volume":"123","author":"Brams","year":"2011","journal-title":"Postgrad Med"},{"issue":"4","key":"zoi250343r80","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.euroneuro.2014.01.007","article-title":"OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.","volume":"24","author":"Bron","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"zoi250343r81","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3810\/pgm.2010.09.2196","article-title":"Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit\/hyperactivity disorder in adults.","volume":"122","author":"Brown","year":"2010","journal-title":"Postgrad Med"},{"issue":"4","key":"zoi250343r82","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/cap.2009.0007","article-title":"Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit\/hyperactivity disorder.","volume":"19","author":"Childress","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"zoi250343r83","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1089\/cap.2019.0085","article-title":"Randomized, double-blind, placebo-controlled, flexible-dose titration study of methylphenidate hydrochloride extended-release capsules (Aptensio XR) in preschool children with attention-deficit\/hyperactivity disorder.","volume":"30","author":"Childress","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"zoi250343r84","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jaac.2022.03.034","article-title":"Efficacy and safety of lisdexamfetamine in preschool children with attention-deficit\/hyperactivity disorder.","volume":"61","author":"Childress","year":"2022","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"zoi250343r85","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.euroneuro.2012.11.012","article-title":"European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder.","volume":"23","author":"Coghill","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"zoi250343r86","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jaac.2014.01.017","article-title":"Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder: randomized-withdrawal study design.","volume":"53","author":"Coghill","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"zoi250343r87","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4088\/JCP.v69n0120","article-title":"A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit\/hyperactivity disorder.","volume":"69","author":"Findling","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"zoi250343r88","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/cap.2019.0125","article-title":"Pre-existing comorbid emotional symptoms moderate short-term methylphenidate adverse effects in a randomized trial of children with attention-deficit\/hyperactivity disorder.","volume":"30","author":"Froehlich","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"zoi250343r89","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1192\/bjp.bp.111.092940","article-title":"Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension.","volume":"200","author":"Ginsberg","year":"2012","journal-title":"Br J Psychiatry"},{"issue":"10","key":"zoi250343r90","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40263-014-0180-4","article-title":"Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study.","volume":"28","author":"Ginsberg","year":"2014","journal-title":"CNS Drugs"},{"issue":"1","key":"zoi250343r91","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4088\/JCP.15m10348","article-title":"Randomized, 6-week, placebo-controlled study of treatment for adult attention-deficit\/hyperactivity disorder: individualized dosing of Osmotic-Release Oral System (OROS) methylphenidate with a goal of symptom remission.","volume":"78","author":"Goodman","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"zoi250343r92","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.3.e39","article-title":"A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit\/hyperactivity disorder.","volume":"109","author":"Greenhill","year":"2002","journal-title":"Pediatrics"},{"issue":"3","key":"zoi250343r93","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1089\/cap.2020.0104","article-title":"A Randomized, double-blind, placebo-controlled, two-way crossover clinical trial of ORADUR-methylphenidate for treating children and adolescents with attention-deficit\/hyperactivity disorder.","volume":"31","author":"Huang","year":"2021","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"zoi250343r94","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12325-013-0085-5","article-title":"Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.","volume":"31","author":"Huss","year":"2014","journal-title":"Adv Ther"},{"issue":"2","key":"zoi250343r95","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4088\/JCP.v68n0213","article-title":"Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit\/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.","volume":"68","author":"Jain","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"zoi250343r96","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/add.12369","article-title":"Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.","volume":"109","author":"Konstenius","year":"2014","journal-title":"Addiction"},{"issue":"6","key":"zoi250343r97","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1017\/S0033291703001776","article-title":"Efficacy and safety of methylphenidate in 45 adults with attention-deficit\/hyperactivity disorder: a randomized placebo-controlled double-blind cross-over trial.","volume":"34","author":"Kooij","year":"2004","journal-title":"Psychol Med"},{"key":"zoi250343r98","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-244X-11-70","article-title":"Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD.","volume":"11","author":"Lee","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"9","key":"zoi250343r99","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/add.12608","article-title":"Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.","volume":"109","author":"Ling","year":"2014","journal-title":"Addiction"},{"issue":"3","key":"zoi250343r100","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3810\/pgm.2008.09.1910","article-title":"Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit\/hyperactivity disorder: a secondary analysis.","volume":"120","author":"Lopez","year":"2008","journal-title":"Postgrad Med"},{"issue":"2","key":"zoi250343r101","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40261-013-0156-z","article-title":"Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit\/hyperactivity disorder.","volume":"34","author":"Martin","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"10","key":"zoi250343r102","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.biopsych.2007.11.008","article-title":"A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit\/hyperactivity disorder.","volume":"63","author":"Medori","year":"2008","journal-title":"Biol Psychiatry"},{"key":"zoi250343r103","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.drugalcdep.2015.05.042","article-title":"Pilot study of the effects of lisdexamfetamine on cocaine use: a randomized, double-blind, placebo-controlled trial.","volume":"153","author":"Mooney","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zoi250343r104","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1176\/appi.ajp.2007.05091676","article-title":"Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.","volume":"165","author":"Newcorn","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"5","key":"zoi250343r105","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/cap.2012.0096","article-title":"Effects of extended release methylphenidate treatment on ratings of attention-deficit\/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms.","volume":"23","author":"Pearson","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"zoi250343r106","doi-asserted-by":"publisher","DOI":"10.1542\/peds.107.6.e105","article-title":"Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.","volume":"107","author":"Pelham","year":"2001","journal-title":"Pediatrics"},{"issue":"6","key":"zoi250343r107","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/01.chi.0000157548.48960.95","article-title":"A dose-ranging study of a methylphenidate transdermal system in children with ADHD.","volume":"44","author":"Pelham","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"zoi250343r108","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1097\/01.chi.0000140455.96946.2b","article-title":"Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit\/hyperactivity disorder.","volume":"43","author":"Quinn","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"zoi250343r109","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1089\/cap.2013.0114","article-title":"Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit\/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.","volume":"24","author":"Ramtvedt","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"zoi250343r110","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3109\/15622975.2010.540257","article-title":"Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.","volume":"13","author":"Retz","year":"2012","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"zoi250343r111","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00406-008-0845-4","article-title":"A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit\/hyperactivity disorder.","volume":"259","author":"R\u00f6sler","year":"2009","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"5","key":"zoi250343r112","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/cap.2009.0106","article-title":"A double-blind, randomized, placebo\/active controlled crossover evaluation of the efficacy and safety of Ritalin \u00ae LA in children with attention-deficit\/hyperactivity disorder in a laboratory classroom setting.","volume":"20","author":"Schulz","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"zoi250343r113","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1089\/cap.2005.15.637","article-title":"Efficacy of two long-acting methylphenidate formulations in children with attention-deficit\/hyperactivity disorder in a laboratory classroom setting.","volume":"15","author":"Silva","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"zoi250343r114","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.biopsych.2006.07.032","article-title":"Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit\/hyperactivity disorder.","volume":"61","author":"Spencer","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"5","key":"zoi250343r115","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.5.e404","article-title":"A dose-response study of OROS methylphenidate in children with attention-deficit\/hyperactivity disorder.","volume":"112","author":"Stein","year":"2003","journal-title":"Pediatrics"},{"issue":"10","key":"zoi250343r116","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1177\/1087054719896853","article-title":"Efficacy and safety of PRC-063, extended-release multilayer methylphenidate in adults with ADHD including 6-month open-label extension.","volume":"25","author":"Weiss","year":"2021","journal-title":"J Atten Disord"},{"issue":"11","key":"zoi250343r117","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1097\/01.chi.0000138351.98604.92","article-title":"A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit\/hyperactivity disorder.","volume":"43","author":"Wigal","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"zoi250343r118","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1097\/01.chi.0000235082.63156.27","article-title":"Safety and tolerability of methylphenidate in preschool children with ADHD.","volume":"45","author":"Wigal","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"zoi250343r119","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01136-6","article-title":"Randomized, double-blind, placebo-controlled trial on the efficacy, safety and tolerability of modified-release methylphenidate (MPH-MR) in Chinese children and adolescents with attention-deficit\/hyperactivity disorder (ADHD).","volume":"39","author":"Zheng","year":"2025","journal-title":"CNS Drugs"},{"issue":"12","key":"zoi250343r120","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.4088\/JCP.09m05335pur","article-title":"Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit\/hyperactivity disorder.","volume":"70","author":"Adler","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"S15","key":"zoi250343r121","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1017\/S1092852900014115","article-title":"Short- and long-term cardiovascular effects of mixed amphetamine salts extended-release in adolescents with ADHD.","volume":"10","author":"Wilens","year":"2005","journal-title":"CNS Spectr"},{"issue":"12","key":"zoi250343r122","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1017\/S1092852900002406","article-title":"Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD.","volume":"10","author":"Biederman","year":"2005","journal-title":"CNS Spectr"},{"issue":"9","key":"zoi250343r125","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"zoi250343r126","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40263-012-0019-9","article-title":"Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.","volume":"27","author":"Martinez-Raga","year":"2013","journal-title":"CNS Drugs"},{"key":"zoi250343r127","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1208456","article-title":"Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the Food and Drug Administration adverse event reporting system.","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"zoi250343r128","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaac.2021.03.019","article-title":"Long-term treatment with extended-release methylphenidate treatment in children aged 4 to <6 years.","volume":"61","author":"Childress","year":"2022","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"zoi250343r129","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/jcpp.12164","article-title":"Stimulant ADHD medication and risk for substance abuse.","volume":"55","author":"Chang","year":"2014","journal-title":"J Child Psychol Psychiatry"},{"issue":"1","key":"zoi250343r130","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1024\/1422-4917\/a000828","article-title":"International Consensus Statement for the screening, diagnosis, and treatment of adolescents with concurrent attention-deficit\/hyperactivity disorder and substance use disorder.","volume":"50","author":"\u00d6zgen","year":"2021","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"issue":"4","key":"zoi250343r131","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/add.15242","article-title":"Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?","volume":"116","author":"Brandt","year":"2021","journal-title":"Addiction"},{"issue":"2","key":"zoi250343r132","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.psc.2012.03.012","article-title":"Psychostimulant treatment of cocaine dependence.","volume":"35","author":"Mariani","year":"2012","journal-title":"Psychiatr Clin North Am"},{"issue":"7","key":"zoi250343r133","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/pds.4003","article-title":"Characteristics of state prescription drug monitoring programs: a state-by-state survey.","volume":"25","author":"Manasco","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"25","key":"zoi250343r134","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1056\/NEJMp1204493","article-title":"Medication reconciliation for controlled substances\u2013an \u201cideal\u201d prescription-drug monitoring program.","volume":"366","author":"Perrone","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi250343r135","first-page":"145","article-title":"ADHD stimulants and their effect on height in children.","volume":"56","author":"Goldman","year":"2010","journal-title":"Can Fam Physician"},{"key":"zoi250343r24","unstructured":"jamovi. Version 2.5. Accessed January 31, 2025. https:\/\/www.jamovi.org\/"},{"key":"zoi250343r25","unstructured":"Review Manager 5 (RevMan 5), version 5.4. The Cochrane Collaboration. 2020. Accessed January 31, 2025. https:\/\/test-training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/review-manager-revman\/download-revman-5"},{"key":"zoi250343r26","unstructured":"R: A language and environment for statistical computing. Version 4.4.2. R Project for Statistical Computing. 2024. Accessed February 3, 2025. https:\/\/www.r-project.org\/"},{"key":"zoi250343r123","unstructured":"U.S. Food and Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. 2023. Accessed January 31, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions"},{"key":"zoi250343r124","unstructured":"U.S. Food and Drug Administration. What is a serious adverse event? Accessed January 30, 2025. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2833773\/oliva_2025_oi_250343_1746203849.72376.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T15:30:44Z","timestamp":1746804644000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2833773"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":135,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.9492","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}